Dublin, May 30, 2018 (GLOBE NEWSWIRE) — The ” What’s Trending in Monoclonal Antibodies (Market by Structure [Chimeric, Humanized], by Target [EGFR, TNF, HER2, CD20,PD-1, Other] and by Disease [Autoimmune, Oncology, Neurological, Other])” report has been added to ResearchAndMarkets.com’s offering.
Monoclonal antibodies (mAbs) – large protein molecules produced by white blood cells (WBCs) that seek out and destroy harmful foreign substances – are finding wide application in many areas of medicine and biologic science. These antibodies have begun to replace conventional antibodies in blood banking and are used in the identification of organisms in the bacteriology laboratory. Monoclonal antibodies have also been extensively used in radioimmunoassay to measure serum levels of various substances. They have very useful in quantitating types of WBCs and subgroups of lymphocytes. They are also used in the diagnosis of leukemia. More recently, monoclonal antibodies have been used in the treatment of malignancies. They have been used to treat transplant rejection episodes, purge bone marrow of tumor cells in bone marrow transplants, and remove mature T cells that cause GVH disease in bone marrow transplants. There are several types of monoclonal antibodies on the market and in development.
What’s Trending in Monoclonal Antibodies provides analysis of the current global market, looking at the market by structure, by target, and by indication, including the following data points:
- Monoclonal Antibody Market by Structure, 2017 and Forecast 2022 (Chimeric, Humanized, Human, Others)
- Leading Products: Chimeric Structure mAb Market, 2017-2022
- Leading Products: Humanized Structure mAb Market, 2017-2022
- Leading Products: Human Structure mAb Market, 2017-2022
- Monoclonal Antibody Market by Target, 2017 and Forecast 2022 (TNF, CD20, HER2, VEGF, EGFR, PD-1, PD-L1, TNFSF11, IL12/IL23, IL17, IL6, Others)
- Monoclonal Antibody Market by Indication, 2017 and Forecast 2022 (Autoimmune, Oncology, Neurological, Respiratory, Cardio/Blood, Infection, Other)
In terms of indication, the monoclonal antibody market is largely derived from treatments in the autoimmune and oncology segments, with other segments representing a smaller share of the market at the current time. By 2022, there is expected to be some shift in sales distribution to other segments.
The report goes beyond broad indication category to provide detail on the following segments:
- Rheumatoid Arthritis mAb Market, 2017-2022
- Crohn’s Disease/Ulcerative Colitis mAb Market, 2017-2022
- Psoriasis mAb Market, 2017-2022
- Other Autoimmune Disease mAb Market, 2017-2022
- Cancer Treatment mAb Market by Type, 2017-2022 (Breast Cancer, Colon Cancer, Lymphoma, Leukemia, Myeloma, Melanoma)
- Top 10 Cancer Indicated Monoclonal Antibodies, 2016 and 2017 Sales
- Multiple Sclerosis mAb Market, 2017-2022
- Asthma mAb Market, 2017-2022
- Macular Degeneration mAb Market, 2017-2022
What’s Trending in Monoclonal Antibodies (Markets by Structure, by Target, and by Indication) also looks at the market in terms of regional markets and the competitive situation. Developments in regional markets are a major driver for the monoclonal antibody market. The report provides an overview of these markets, going beyond the U.S. market to discuss the Europe market and rest of world market, which largely includes the Asia Pacific markets including Japan. Further, the report provides a competitor summary. It is no surprise that the early developers of monoclonal antibodies continue to be the leaders in the segment today. Some two decades ago, Abbott (with MedImmune), Johnson & Johnson (with Centocor) and Roche (with Genentech) launched three of today’s leading mAb therapies.
Data provided include:
- Monoclonal Antibody Market Summary by Geographical Region, 2017-2022 (United States, Europe, Rest of World, Global Market)
- Monoclonal Antibody Competitor Market Share, 2017
Company profiles of the major participants in the monoclonal antibody market are provided, including:
- AbbVie
- Ablynx
- Agensys
- Alder Biopharmaceuticals
- Alexion Pharmaceuticals
- Allergan
- Amgen
- Aptevo Therapeutics
- AstraZeneca/MedImmune
- Bayer
- Biocon Ltd
- Biogen Inc.
- BioInvent International
- Biotest AG
- Boehringer Ingelheim GmbH
- CBT Pharmaceuticals
- Celgene
- Celldex Therapeutics
- Celltrion, Inc.
- Coherus BioSciences, Inc
- CytoDyn
- Eisai
- Eleven Biotherapeutics
- Eli Lilly & Co.
- FibroGen Inc.
- Five Prime Therapeutics
- Fujifilm Kyowa Kirin Biologics
- Genmab A/S
- Gilead Sciences
- GlaxoSmithKline plc
- Humanigen, Inc. (previously KaloBios Pharmaceuticals)
- Immune Pharmaceuticals
- ImmunoGen Inc.
- Immunomedics Inc.
- Innate Pharma
- InterveXion Therapeutics
- Johnson & Johnson
- Kyowa Hakko Kirin Co, Ltd
- MacroGenics
- Mapp Biopharmaceutical
- Merck & Company
- Merrimack Pharmaceuticals
- Momenta Pharmaceuticals Inc.
- MorphoSys
- Morphotek
- Mylan N.V.
- Nascent Biotech
- Neurimmune
- Nordic Nanovector
- Novartis/Sandoz
- Novimmune SA
- OncoMed Pharmaceuticals
- OncoQuest
- Oncternal Therapeutics
- Pfizer, Inc.
- Regeneron Pharmaceuticals
- Roche
- Samsung Bioepis Co Ltd
- Sanofi
- Seattle Genetics
- Shire PLC
- Sorrento Therapeutics
- TaiMed Biologics
- Takeda Oncology
- TESARO
- TEVA Pharmaceutical Industries Ltd
- TG Therapeutics
- ThromboGenics
- UCB S.A.
- Unum Therapeutics
- Vitaeris
- XBiotech
- Xencor
- XOMA
- Y-mAbs Therapeutics
Key Topics Covered:
1. Executive Summary
- Overview
- Scope and Methodology
- Market Summary
2. Introduction
- The Development of Monoclonal Antibodies
- Table Monoclonal Antibody Approvals by Year, FDA and EMA, 1990 through December 2017
- Naming Monoclonal Antibodies
- New Monoclonal Antibody Nomenclature Rules
- DEVELOPMENT Outlook
3. Monoclonal Antibody Markets by Structure
- Table Monoclonal Antibodies by Structure – Mouse, Chimeric, Humanized, Human
- Market Overview
- Chimeric
- Humanized
- Human
4. Monoclonal Antibody Markets by Target
- Market Overview
5. Monoclonal Antibody Markets by Indication
- Market Overview
- Autoimmune Diseases
- Oncology Indications
- Neurological Indications
- Respiratory Treatments
- Other Areas of Treatment
6. Market Summary
- Market Influences
- Global Demographics
- Chronic Diseases
- Cost Containment
- Reimbursement Landscape: A Deciding Factor for Success
- The Biosimilar Movement
- Regional Market Overview
- Leading Products
- Market Breakdown of Monoclonal Antibodies
- Competitor Summary
- Genentech/Roche
- AbbVie
- Janssen Biotech/J&J
- Bristol-Myers Squibb
- Merck & Co.
- Novartis
- Amgen
- Alexion
- Biogen
- Eli Lilly & Co.
7. Company Profiles
- AbbVie
- Ablynx
- Agensys
- Alder Biopharmaceuticals
- Alexion Pharmaceuticals
- Allergan
- Amgen
- Aptevo Therapeutics
- AstraZeneca/MedImmune
- Bayer
- BioInvent International
- Biocon Ltd
- Biogen Inc.
- Biotest AG
- Boehringer Ingelheim GmbH
- CBT Pharmaceuticals
- Celgene
- Celldex Therapeutics
- Celltrion, Inc.
- Coherus BioSciences, Inc
- CytoDyn
- Eisai
- Eleven Biotherapeutics
- Eli Lilly & Co.
- FibroGen Inc.
- Five Prime Therapeutics
- Fujifilm Kyowa Kirin Biologics
- Genmab A/S
- Gilead Sciences
- GlaxoSmithKline plc
- Humanigen, Inc. (previously KaloBios Pharmaceuticals)
- Immune Pharmaceuticals
- ImmunoGen Inc.
- Immunomedics Inc.
- Innate Pharma
- InterveXion Therapeutics
- Johnson & Johnson
- Kyowa Hakko Kirin Co, Ltd
- MacroGenics
- Mapp Biopharmaceutical
- Merck & Company
- Merrimack Pharmaceuticals
- Momenta Pharmaceuticals Inc.
- MorphoSys
- Morphotek
- Mylan N.V.
- Nascent Biotech
- Neurimmune
- Nordic Nanovector
- Novartis/Sandoz
- Novimmune SA
- OncoMed Pharmaceuticals
- OncoQuest
- Oncternal Therapeutics
- Pfizer, Inc.
- Regeneron Pharmaceuticals
- Roche
- Samsung Bioepis Co Ltd
- Sanofi
- Seattle Genetics
- Shire PLC
- Sorrento Therapeutics
- TESARO
- TEVA Pharmaceutical Industries Ltd
- TG Therapeutics
- TaiMed Biologics
- Takeda Oncology
- ThromboGenics
- UCB S.A.
- Unum Therapeutics
- Vitaeris
- XBiotech
- XOMA
- Xencor
- Y-mAbs Therapeutics
For more information about this report visit https://www.researchandmarkets.com/research/d4sblh/whats_trending?w=12
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Biopharmaceuticals , Oncology
